Establishment Labs Holdings Inc. (ESTA) on Monday said it has submitted Motiva implants to the U.S. Food and Drug Administration for approval in primary and revision breast reconstruction.
The submission is supported by data from the Motiva U.S. IDE Study, which included 274 post-mastectomy reconstruction patients, comprising 220 primary and 54 revision cases. The company said Motiva SmoothSilk Round and Ergonomix implants represent state-of-the-art innovation in plastic surgery.
Motiva implants were previously approved by the FDA for breast augmentation in September 2024. Since that approval, more than 60,000 Motiva implants have been sold in the United States, the company said.
In addition, the Motiva Flora tissue expander was cleared for use in the U.S. in 2023 and is currently used at more than 200 cancer centers for breast reconstruction following breast cancer.
Establishment Labs closed Friday's trading at $76.45, up 1.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.